NT2

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Retrieved on: 
Thursday, February 8, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, MRCP, Hepatotoxicity, NT2, Neurological disorder, Narcolepsy, WCR, Fiscal, Wakefulness, Caregiver, Head, Patient, ESS, DSM-IV codes, Medicine, Neuron, OX2R, Disease, Epworth Sleepiness Scale, MWT, Pharmaceutical industry

It is currently classified into two different types: narcolepsy type 1 (NT1) caused by significant loss of orexin neurons with resulting lack of orexin, and narcolepsy type 2 (NT2) where orexin levels are generally normal.

Key Points: 
  • It is currently classified into two different types: narcolepsy type 1 (NT1) caused by significant loss of orexin neurons with resulting lack of orexin, and narcolepsy type 2 (NT2) where orexin levels are generally normal.
  • Stimulating the orexin receptor 2 in NT1 patients targets the underlying pathophysiology of the disease to restore orexin signaling.
  • Based on these results, and in consultation with global health authorities, Takeda plans to initiate global Phase 3 trials of TAK-861 in NT1 rapidly in the first half of its fiscal year 2024.
  • Results from the Phase 2b trials have no impact on the full year consolidated reported forecast for the fiscal year ending March 31, 2024 (Fiscal Year 2023).

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

Retrieved on: 
Wednesday, October 25, 2023
IH, BRT, Wakefulness, Sleep, Cataplexy, IND, NT2, Human, Congress, Narcolepsy, Electromyography, DTA, Idiopathic hypersomnia, OX2R, OX1R, PK, EC50, EMG, EEG, CHO, Patient, CNTA, Pharmaceutical industry, Aroma compound, Surat Bus Rapid Transit System, NT1

BOSTON and LONDON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced a robust set of new preclinical data from in vivo and in vitro studies of its investigational, novel orexin receptor 2 (OX2R) agonist, ORX750, that support its potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders.

Key Points: 
  • “The preclinical data showed ORX750 achieved maximal wake times and suppressed cataplexy at 0.1 mg/kg, the lowest oral dose tested in the DTA mouse model.
  • Notably, this activity was observed in both the DTA and Atax mouse models that recapitulate NT1 symptoms in humans.
  • Fluorescent imaging plate reader (FLIPR) assay with Chinese hamster ovary (CHO) cells stably expressing recombinant human OX1R or OX2R; OXA EC50 at hOX2R = 0.035 nM.
  • As measured by electroencephalogram (EEG) and electromyogram (EMG) with concurrent video in DTA and Atax mouse models.

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023

Retrieved on: 
Friday, October 20, 2023
FDA, Headache, Narcolepsy, Incidence, NT2, Food, Health, Vomiting, Dizziness, Epworth Sleepiness Scale, Cataplexy, Nausea, Poster, Senior, EDS, Disease, Enuresis, Avadel Pharmaceuticals, World Sleep Day, Sodium oxybate, Doctor of Pharmacy, Body mass index, Sleep, CIII, Mitigation, Patient, Central nervous system, Pharmaceutical industry, Dietary supplement, NT1

DUBLIN, Ireland, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new and encore data supporting the clinical profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) and patient preference for a once-nightly oxybate in 15 poster presentations and two oral presentations, at World Sleep 2023, being held from October 20-25, 2023 in Rio de Janeiro, Brazil. LUMRYZ (previously known as FT218), is a U.S. Food and Drug Administration (FDA) approved extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

Key Points: 
  • “We are excited to be at this year’s World Sleep meeting with another robust display of data that supports both the established clinical benefit of LUMRYZ,” said Jennifer Gudeman, PharmD, Senior Vice President, Medical and Clinical Affairs of Avadel.
  • “Quality sleep is a foundational pillar of health for people with narcolepsy, yet ~65% of patients with narcolepsy experience poor, fragmented sleep in addition to their daytime symptoms.
  • LUMRYZ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy called the LUMRYZ REMS.
  • Most common adverse reactions (incidence > 5% and greater than placebo) reported for all doses of LUMRYZ combined were nausea, dizziness, enuresis, headache, and vomiting.

Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Sodium oxybate, Cataplexy, NT2, Pharmacy, EDS, Narcolepsy, Marketing, Anxiety, Sleep, Sleep Research Society, American depositary receipt, NDA, Prescription, American Academy, U.S. FDA, Avadel Pharmaceuticals, American Academy of Sleep Medicine, Patient, NT1, ESI, Somnolence, Growth, FDA, Health, Pharmaceutical industry, Nursing, Fine chemical

DUBLIN, Ireland, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the second quarter ended June 30, 2023.

Key Points: 
  • ET --
    DUBLIN, Ireland, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the second quarter ended June 30, 2023.
  • Recognized $1.5 million in net product revenues for the second quarter 2023.
  • R&D expenses were $4.2 million in the quarter ended June 30, 2023, compared to $4.5 million for the same period in 2022.
  • SG&A expenses were $46.8 million in the quarter ended June 30, 2023, compared to $21.8 million for the same period in 2022.

NIO Emerging Carmaker Strategy Research Report 2023: ES6, ET7 and EC6 were the Top Three Models by Sales - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 1, 2023
Automotive Manufacturing, Manufacturing, Atmos, EC6, HD, EEA, Habit, NT2, ADAM, Smartphone, Evocation, Anxiety, OTA, NOP, Perception, IVI, Firefly, NIO, HUD, Lidar, BEV, ALPS, USS, NT3, Radar, ES6, Algorithm, NP, NT1, Architecture, City, Ecosystem, XR, ES7, Dolby Atmos, Navigation, AR, Software, Retail, Satellite navigation device, Rail transport, Instrumentation

The "Emerging Carmaker Strategy Research Report, 2023 - NIO" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Emerging Carmaker Strategy Research Report, 2023 - NIO" report has been added to ResearchAndMarkets.com's offering.
  • As ES7, ET7 and ET5 ("775") were delivered, they saw a rising share of sales.
  • By province, Zhejiang (26,747 units), Jiangsu (18,105 units) and Guangdong (15,626 units) ranked top three by sales.
  • At present, all the cars delivered by NIO are positioned as high-end models priced at higher than RMB300,000.

Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022)

Retrieved on: 
Tuesday, September 20, 2022
Cataplexy, Safety, COVID-19, CNTA, Risk, MD, Drug, Drug design, U.S. Securities and Exchange Commission, Narcolepsy, IND, Wakefulness, Company, Sleep, Poster, OX1R, Industry, Cryogenic electron microscopy, Maintenance, WT, Head, Patient, NT2, Program, Clinical trial, OX2R, Annual report, Nasdaq, Omicron, Doctor of Philosophy, NT1, Research, Conference, GLOBE, SEC, Awareness, Disease, Research and development, Pharmaceutical industry, Delta

BOSTON and LONDON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that non-clinical data from its oral orexin receptor 2 (OX2R) agonist discovery pipeline have been accepted for poster presentation at the 26th Conference of the European Sleep Research Society meeting (Sleep Europe 2022) being held on September 27-30, 2022, in Athens, Greece. Centessa’s OX2R agonists are designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 (NT1), with potential expansion into narcolepsy type 2 (NT2), and other sleep disorders.

Key Points: 
  • These novel OX2R agonist compounds showed high potency in activating recombinant human and endogenous mouse OX2Rs, with more than a thousand-fold selectivity for OX2R compared to OX1R.
  • Our innovative pipeline is both a testament to their expertise and strong validation of our approach to structure-based drug design.
  • We are encouraged by the non-clinical data and are rapidly progressing several potentially best-in-class oral small-molecule OX2R agonists through our discovery pipeline.
  • We are excited to showcase some of our small-molecule OX2R agonist discovery pipeline and share these data at Sleep Europe 2022, said Mario Alberto Accardi, PhD, Head, Centessa Orexin Program.

NIO Inc. Provides August 2022 Delivery Update

Retrieved on: 
Thursday, September 1, 2022
Shanghai Stock Exchange STAR Market, ES7, NYSE, Solution, EC6, Sport utility vehicle, NT2, ES6, SEHK, NIO, ES8, Electric Bond and Share Company v. Securities and Exchange Commission, Battery, Mobile backend as a service, GLOBE, HKEX, Publication, 2600-series (CTA), Stock exchange, Adaa Khan, Motor vehicle, Terminology, SUV, Annual report, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Forward-looking statement, Propane, Taxicab, Risk management

SHANGHAI, China, Sept. 01, 2022 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the premium smart electric vehicle market, today announced its August 2022 delivery results.

Key Points: 
  • NIO delivered 10,677 vehicles in August 2022, increasing by 81.6% year-over-year
    NIO delivered 71,556 vehicles year-to-date 2022, increasing by 28.3% year-over-year
    Cumulative deliveries of NIO vehicles reached 238,626 as of August 31, 2022
    SHANGHAI, China, Sept. 01, 2022 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (NIO or the Company), a pioneer and a leading company in the premium smart electric vehicle market, today announced its August 2022 delivery results.
  • NIO delivered 10,677 vehicles in August 2022, representing an increase of 81.6% year-over-year.
  • Cumulative deliveries of NIO vehicles reached 238,626 as of August 31, 2022.
  • In August, the production and delivery of the ES7, a mid-large five-seater premium smart electric SUV based on NIO Technology 2.0 (NT2), started to ramp up steadily.

EV Group Achieves Die-to-Wafer Fusion and Hybrid Bonding Milestone with 100-Percent Die Transfer Yield on Multi-Die 3D System-on-a-Chip

Retrieved on: 
Tuesday, July 12, 2022
Technology, Feedback, Moscone Center, Multimedia, Artificial intelligence, Semiconductor, Solution, 3D, Microelectromechanical systems, NIL, ACE EV Group, EVG, View, NT2, W2W, SOC, IP, FB, MEMS, GEMINI, AI, Plasma, Nanotechnology, Antioch Hall, North and South Halls, Printed circuit board, Video game console

ST. FLORIAN, Austria, July 12, 2022 /PRNewswire/ -- EV Group (EVG), a leading provider of wafer bonding and lithography equipment for the MEMS, nanotechnology and semiconductor markets, today announced it has achieved a major breakthrough in die-to-wafer (D2W) fusion and hybrid bonding by successfully demonstrating 100-percent void-free bonding yield of multiple die of different sizes from a complete 3D system-on-a-chip (SoC) in a single transfer process using EVG's GEMINI®FB automated hybrid bonding system. Such an accomplishment had been a key challenge for D2W bonding until today, as well as a major hurdle to scaling down the cost of implementing heterogeneous integration. This important industry achievement was carried out at EVG's Heterogeneous Integration Competence Center™ (HICC), which is designed to assist customers in leveraging EVG's process solutions and expertise to accelerate the development of new and differentiating products and applications driven by advances in system integration and packaging.

Key Points: 
  • D2W hybrid bonding is a key manufacturing technology for heterogeneous integration.
  • Yet, as the ever-higher bandwidth needs of these devices drive newer packaging technologies, new developments in D2W hybrid bonding and metrology are also needed.
  • In addition, several different D2W hybrid bonding process flows are under evaluation today, each with unique advantages and requirements.
  • Founded in 1980, EV Group services and supports an elaborate network of global customers and partners all over the world.

NIO Inc. Provides March and First Quarter 2022 Delivery Update

Retrieved on: 
Friday, April 1, 2022
NIO ES6, Company, NIO ET7, ES8, Mobile backend as a service, SUV, NIO ES8, 2600-series (CTA), Forward-looking statement, NYSE, City, Annual report, Motor vehicle, Publication, Battery, EC6, Adaa Khan, Private Securities Litigation Reform Act, Shanghai Stock Exchange STAR Market, NT2, U.S. Securities and Exchange Commission, Stock exchange, Electric Bond and Share Company v. Securities and Exchange Commission, GLOBE, Solution, Sport utility vehicle, NIO, ES6, Terminology, NIO EC6, Propane, Video game

NIO delivered 25,768 vehicles in the first quarter 2022, a new quarterly record, representing an increase of 28.5% year-over-year.

Key Points: 
  • NIO delivered 25,768 vehicles in the first quarter 2022, a new quarterly record, representing an increase of 28.5% year-over-year.
  • In the meantime, NIO ES7, the Companys new mid-to-large five-seater SUV equipped with NIO Technology 2.0 (NT2), will also make its debut.
  • As of March 31, 2022, NIO has deployed 884 Power Swap stations, 727 Power Charger stations and 3,832 destination chargers in China.
  • NIO launched the ET7, a flagship premium smart electric sedan, in January 2021, and began deliveries of the ET7 in March 2022.

EV Group Brings High-Speed High-Precision Metrology To 3D Heterogeneous Integration

Retrieved on: 
Monday, November 15, 2021
Learning, EVG, Microelectromechanical systems, Industry, Maskless lithography, NIL, D2D, 3D, ACE EV Group, NT2, Nanotechnology, MEMS, Semiconductor, Solution, Silicon, Printed circuit board

"Process control is increasingly critical for leading-edge 3D and heterogeneous integration applications," stated Dr. Thomas Glinsner, corporate technology director at EV Group.

Key Points: 
  • "Process control is increasingly critical for leading-edge 3D and heterogeneous integration applications," stated Dr. Thomas Glinsner, corporate technology director at EV Group.
  • The EVG40 NT2 is already playing a key role in several joint development projects underway at EVG's Heterogeneous Integration Competence Center."
  • EVG is now accepting orders for the new EVG40 NT2 automated metrology system, and offering product demonstrations at EVG's Heterogeneous Integration Competence Center at its headquarters in Austria.
  • Founded in 1980, EV Group services and supports an elaborate network of global customers and partners all over the world.